Oct. 3 at 5:27 PM
At
$CRBU the chart continues to hold structure with
$2.14 now acting as solid support after multiple successful retests. Each pullback has been absorbed with steady volume, showing buyers are in control and pressing higher with intent. The asymmetric setup remains intact as long as
$2.14 holds, with
$2.88+ firmly on the radar.
Beyond the chart, fundamentals line up with the technicals. Hiring has quietly resumed in quality and clinical ops, a signal that internal execution is accelerating after last year’s consolidation. With CB-010 and CB-011 data still expected before year-end and Pfizer’s RoFN agreement still active, catalysts are stacking into Q4.
This is a name that has digested supply, rebuilt its base, and is starting to expand with conviction. Momentum is there, the setup is coiled, and the next leg higher is open.
